# US 2016/0250301 A1 · Long-acting coagulation factors and methods of producing same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250301 A1
- Document ID: US20160250301A1
- Status: Published application
- Kind: A1
- Application number: 15/159,641
- Filed: 2016-05-19
- Published: 2016-09-01
- Earliest claimed: 2009-07-09
- Assignees: OPKO Biologics Ltd.
- Applicants: OPKO Biologics Ltd.
- Inventors: Udi Eyal FIMA; Gili HART
- Web page: https://patentgrep.com/patent/US20160250301A1

## CPC

- C12N 9/64: derived from animal tissue
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- C07K 14/505: Erythropoietin [EPO]
- C07K 14/59: Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- C07K 14/745: Blood coagulation or fibrinolysis factors
- C12N 9/6437: {Coagulation factor VIIa (3.4.21.21)}
- C12N 9/644: {Coagulation factor IXa (3.4.21.22)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/02: containing a signal sequence
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C07K 2319/91: containing a motif for glycosylation
- C12Y 304/21021: Coagulation factor VIIa (3.4.21.21)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.

## Claims

### Claim 1

A CTP-modified polypeptide consisting of a coagulation factor and three to five chorionic gonadotropin carboxy terminal peptides (CTPs) attached to the carboxy terminus of said coagulation factor, wherein at least one CTP is optionally attached to said coagulation factor via a linker, and wherein said coagulation factor is selected from Factor VII (FVII) and activated Factor VII (FVIIa).

### Claim 2 (depends on 1)

The CTP-modified polypeptide of claim 1, wherein the sequence of at least one CTP is selected from the group consisting of: SEQ ID NO: 1 and SEQ ID NO: 2.

### Claim 3 (depends on 1)

The CTP-modified polypeptide of claim 1, wherein at least one CTP is glycosylated.

### Claim 4 (depends on 1)

The CTP-modified polypeptide of claim 1, wherein at least one CTP is truncated.

### Claim 5 (depends on 1)

The CTP-modified polypeptide of claim 1, wherein said linker is a peptide bond.

### Claim 6 (depends on 1)

The CTP-modified polypeptide of claim 1, wherein the sequence of said CTP-modified Factor VII (FVII) or activated Factor VII (FVIIa) is selected from the group consisting of: amino acids 39-528 of SEQ ID NO: 25, amino acids 42-534 of SEQ ID NO: 27, amino acids 42-591 of SEQ ID NO: 29, SEQ ID NO: 46, SEQ ID NO: 50, and SEQ ID NO: 51.

### Claim 7 (depends on 1)

The CTP-modified polypeptide of claim 1, wherein said polypeptide further comprises a signal peptide.

### Claim 8 (depends on 7)

The CTP-modified polypeptide of claim 7, wherein said signal peptide is set forth in SEQ ID NO: 47.

### Claim 9 (depends on 7)

The CTP-modified polypeptide of claim 7, wherein the sequence of said CTP-modified FVII or FVIIa is selected from the group consisting of SEQ ID NOs: 25, 27, and 29.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising the CTP-modified polypeptide of claim 1 and a pharmaceutically acceptable carrier.

### Claim 11

A method of extending the biological half-life of a coagulation factor, comprising the step of attaching three to five chorionic gonadotropin carboxy terminal peptides (CTPs) to the carboxy terminus of said coagulation factor, thereby extending the biological half-life of said coagulation factor, wherein at least one CTP is optionally attached to said coagulation factor via a linker, and wherein said coagulation factor is selected from Factor VII (FVII) and activated Factor VII (FVIIa).

### Claim 12 (depends on 11)

The method of claim 11, wherein the sequence of at least one CTP is selected from the group consisting of: SEQ ID NO: 1 and SEQ ID NO: 2.

### Claim 13 (depends on 11)

The method of claim 11, wherein at least one CTP is glycosylated.

### Claim 14 (depends on 11)

The method of claim 11, wherein at least one CTP is truncated.

### Claim 15 (depends on 11)

The method of claim 11, wherein said linker is a peptide bond.

### Claim 16 (depends on 11)

The method of claim 11, wherein the sequence of said CTP-modified Factor VII (FVII) or activated Factor VII (FVIIa) is selected from the group consisting of: amino acids 39-528 of SEQ ID NO: 25, amino acids 42-534 of SEQ ID NO: 27, amino acids 42-591 of SEQ ID NO: 29, SEQ ID NO: 46, SEQ ID NO: 50, and SEQ ID NO: 51.

### Claim 17 (depends on 11)

The method of claim 11, wherein said polypeptide further comprises a signal peptide.

### Claim 18 (depends on 17)

The method of claim 17, wherein said signal peptide is set forth in SEQ ID NO: 47.

### Claim 19 (depends on 17)

The method of claim 17, wherein the sequence of said CTP-modified FVII or FVIIa is selected from the group consisting of SEQ ID NOs: 25, 27, and 29.

### Claim 20

A method of improving the area under the curve (AUC) of a coagulation factor, comprising the step of attaching three to five chorionic gonadotropin carboxy terminal peptides (CTPs) to the carboxy terminus of said coagulation factor, thereby improving the AUC of said coagulation factor, wherein at least one CTP is optionally attached to said coagulation factor via a linker, and wherein said coagulation factor is selected from Factor VII (FVII) and activated Factor VII (FVIIa).

### Claim 21 (depends on 20)

The method of claim 20, wherein the sequence of at least one CTP is selected from the group consisting of: SEQ ID NO: 1 and SEQ ID NO: 2.

### Claim 22 (depends on 20)

The method of claim 20, wherein at least one CTP is glycosylated.

### Claim 23 (depends on 20)

The method of claim 20, wherein at least one CTP is truncated.

### Claim 24 (depends on 20)

The method of claim 20, wherein said linker is a peptide bond.

### Claim 25 (depends on 20)

The method of claim 20, wherein the sequence of said CTP-modified Factor VII (FVII) or activated Factor VII (FVIIa) is selected from the group consisting of: amino acids 39-528 of SEQ ID NO: 25, amino acids 42-534 of SEQ ID NO: 27, amino acids 42-591 of SEQ ID NO: 29, SEQ ID NO: 46, SEQ ID NO: 50, and SEQ ID NO: 51.

### Claim 26 (depends on 20)

The method of claim 20, wherein said polypeptide further comprises a signal peptide.

### Claim 27 (depends on 26)

The method of claim 26, wherein said signal peptide is set forth in SEQ ID NO: 47.

### Claim 28 (depends on 27)

The method of claim 27, wherein the sequence of said CTP-modified FVII or FVIIa is selected from the group consisting of SEQ ID NOs: 25, 27, and 29.

### Claim 29

A method of reducing the dosing frequency of a coagulation factor, comprising the step of attaching three to five chorionic gonadotropin carboxy terminal peptides (CTPs) to the carboxy terminus of said coagulation factor, thereby reducing the dosing frequency of said coagulation factor, wherein at least one CTP is optionally attached to said coagulation factor via a linker, and wherein said coagulation factor is selected from Factor VII (FVII) and activated Factor VII (FVIIa).

### Claim 30 (depends on 29)

The method of claim 29, wherein the sequence of at least one CTP is selected from the group consisting of: SEQ ID NO: 1 and SEQ ID NO: 2.

### Claim 31 (depends on 29)

The method of claim 29, wherein at least one CTP is glycosylated.

### Claim 32 (depends on 29)

The method of claim 29, wherein at least one CTP is truncated.

### Claim 33 (depends on 29)

The method of claim 29, wherein said linker is a peptide bond.

### Claim 34 (depends on 29)

The method of claim 29, wherein the sequence of said CTP-modified Factor VII (FVII) or activated Factor VII (FVIIa) is selected from the group consisting of: amino acids 39-528 of SEQ ID NO: 25, amino acids 42-534 of SEQ ID NO: 27, amino acids 42-591 of SEQ ID NO: 29, SEQ ID NO: 46, SEQ ID NO: 50, and SEQ ID NO: 51.

### Claim 35 (depends on 29)

The method of claim 29, wherein said polypeptide further comprises a signal peptide.

### Claim 36 (depends on 35)

The method of claim 35, wherein said signal peptide is set forth in SEQ ID NO: 47.

### Claim 37 (depends on 36)

The method of claim 36, wherein the sequence of said CTP-modified FVII or FVIIa is selected from the group consisting of SEQ ID NOs: 25, 27, and 29.
